Siegel RL, Miller KD, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

Article  Google Scholar 

Lheureux S, Gourley C, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.

Article  Google Scholar 

Lheureux S, Braunstein M, et al. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.

PubMed  Google Scholar 

Baert T, Ferrero A, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol. 2021;32(6):710–25.

Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.

Article  Google Scholar 

James NE, Woodman M, et al. The perfect combination: enhancing patient response to PD-1-based therapies in epithelial ovarian Cancer. Cancers (Basel). 2020;12(8):2150.

Thorsson V, Gibbs DL, et al. The immune landscape of Cancer. Immunity. 2018;48(4):812–30 e14.

CAS  Article  Google Scholar 

Lu X, Horner JW, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–32.

CAS  Article  Google Scholar 

Xu F, Jin T, et al. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110.

Article  Google Scholar 

Luke JJ, Flaherty KT, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–82.

CAS  Article  Google Scholar 

Domchek SM, Postel-Vinay S, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–64.

CAS  Article  Google Scholar 

Gibb EA, Brown CJ, et al. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.

CAS  Article  Google Scholar 

Zhan L, Li J, et al. Long non-coding RNAs in ovarian cancer. J Exp Clin Cancer Res. 2018;37(1):120.

Article  Google Scholar 

Abildgaard C, Do Canto LM, et al. Long non-coding RNAs involved in resistance to chemotherapy in ovarian Cancer. Front Oncol. 2019;9:1549.

Article  Google Scholar 

Denaro N, Merlano MC, et al. Long noncoding RNAs as regulators of cancer immunity. Mol Oncol. 2019;13(1):61–73.

CAS  Article  Google Scholar 

Qian M, Ling W, et al. Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages. Aging (Albany NY). 2020;12(17):17122–36.

CAS  Article  Google Scholar 

Shang A, Wang W, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res. 2019;38(1):411.

Article  Google Scholar 

Hong W, Liang L, et al. Immune-related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma. Mol Ther Nucleic Acids. 2020;22:937–47.

CAS  Article  Google Scholar 

Ma W, Zhao F, et al. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med. 2020;18(1):442.

CAS  Article  Google Scholar 

Zhang L, Li L, et al. Identification of immune-related lncRNA signature to predict prognosis and immunotherapeutic efficiency in bladder Cancer. Front Oncol. 2020;10:542140.

Article  Google Scholar 

Chen P, Gao Y, et al. A prognostic model based on immune-related long non-coding RNAs for patients with cervical Cancer. Front Pharmacol. 2020;11:585255.

CAS  Article  Google Scholar 

Li Y, Jiang T, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000.

CAS  Article  Google Scholar 

Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516–31.

CAS  Article  Google Scholar 

Bagchi S, Yuan R, et al. Immune checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.

CAS  Article  Google Scholar 

Borella F, Ghisoni E, et al. Immune checkpoint inhibitors in epithelial ovarian Cancer: an overview on efficacy and future perspectives. Diagnostics (Basel). 2020;10(3):146.

Wu M, Fu P, et al. Long noncoding RNAs, new critical regulators in Cancer immunity. Front Oncol. 2020;10:550987.

Article  Google Scholar 

Jiang R, Tang J, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129.

CAS  Article  Google Scholar 

Wu K, Zhao Z, et al. Long noncoding RNA lnc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment. Cell Cycle. 2017;16(13):1295–301.

CAS  Article  Google Scholar 

Huang Y, Luo Y, et al. Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC. Cancer Cell Int. 2021;21(1):528.

CAS  Article  Google Scholar 

Cao K, Liu M, et al. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma. Cancer Immunol Immunother. 2021.

Song S, Liu S, et al. Identification of an immune-related long noncoding RNA pairs model to predict survival and immune features in gastric Cancer. Front Cell Dev Biol. 2021;9:726716.

Article  Google Scholar 

Liang H, Bai Y, et al. Identification of LncRNA prognostic markers for ovarian Cancer by integration of co-expression and CeRNA network. Front Genet. 2020;11:566497.

CAS  Article  Google Scholar 

Liu X, Gao J, et al. Identification of two molecular subtypes of dysregulated immune lncRNAs in ovarian cancer. Exp Biol Med (Maywood). 2021;246(5):547–59.

CAS  Article  Google Scholar 

Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii1–7.

CAS  Article  Google Scholar 

Fucikova J, Coosemans A, et al. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J Immunother Cancer. 2021;9(10):e002873.

Hamanishi J, Mandai M, et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015–22.

CAS  Article  Google Scholar 

Zamarin D, Burger RA, et al. Randomized phase II trial of Nivolumab versus Nivolumab and Ipilimumab for recurrent or persistent ovarian Cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814–23.

CAS  Article  Google Scholar 

Moore KN, Bookman M, et al. Atezolizumab, Bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian Cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842–55.

Article  Google Scholar 

Lieber S, Reinartz S, et al. Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology. 2018;7(5):e1424672.

Article  Google Scholar 

Kroeger DR, Milne K, et al. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, Cytolytic T-cell responses, and superior prognosis in ovarian Cancer. Clin Cancer Res. 2016;22(12):3005–15.

CAS  Article  Google Scholar 

Silveira HS, Lupi LA, et al. P-MAPA activates TLR2 and TLR4 signaling while its combination with IL-12 stimulates CD4+ and CD8+ effector T cells in ovarian cancer. Life Sci. 2020;254:117786.

CAS  Article  Google Scholar 

Galluzzi L, Humeau J, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–41.

Article  Google Scholar 

Nero C, Ciccarone F, et al. Ovarian Cancer treatments strategy: focus on PARP inhibitors and immune check point inhibitors. Cancers (Basel). 2021;13(6):1298.

Le Saux O, Ray-Coquard I, et al. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020.